Turnover€97k-18.8%
EBIT margin-598.8%-254.9pp
Net result€-629k-45.8%
Working capital€-821k-93.0%
Conclusion
the dossier summarised in one paragraphThe computed 12-month bankruptcy probability of C-Biotech is 3.4% (average). The 2024 annual accounts show equity of €195k and a net result of €-629k. The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 2 annual accounts.
Bankruptcy probability (12 mo)
Checked model v1 · free for everyone3.4%
Average
0%0,5%1,5%4%10%≥25%
Young company
+Higher-failure-rate sector
+Multiple establishment units
+
Statistical estimate based on public sources — not credit advice nor a finding of fact. How do we compute this?
Financials
FY 2024
€195k
equity
Turnover€97k
Net result€-629kHealth0/100 · Critical
See full annual accounts
People & board
No director data processed yet.
To directors Publicationslatest 06-06-2025
2
publications in the State Gazette1 director appointed, 1 resigningAll publications & acts Network & structure
No network or structure data processed.
To structure
Trust signals
3 signalsMore than 3 years active
Founded in 2022 — past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad.
Administratively compliant
No FOD Economie strikeouts (UBO, accounts, address, activity).
Administrative Flags
0 events
No administrative flags
Company registry (CBE)
Crossroads BankActivities
Sanering en ander afvalbeheer39000Sanering en ander afvalbeheer39000
Primary activity highlighted.
Names & trade names
| Legal nameNL | C-Biotech |
Registered office
Frank Van Dyckelaan 15
9140 Temse, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.